A5043260959- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Esophageal Cancer Research and Treatment
- Gastrointestinal Tumor Research and Treatment
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Immunotherapy and Immune Responses
- Pancreatitis Pathology and Treatment
- Colorectal and Anal Carcinomas
- Urinary Tract Infections Management
- Immune Cell Function and Interaction
- Cholangiocarcinoma and Gallbladder Cancer Studies
- CAR-T cell therapy research
- Pelvic floor disorders treatments
- Cancer Cells and Metastasis
- Cell Adhesion Molecules Research
- Lung Cancer Treatments and Mutations
- Angiogenesis and VEGF in Cancer
- Neutropenia and Cancer Infections
- HER2/EGFR in Cancer Research
Mayo Clinic
2019-2025
Mayo Clinic in Arizona
2019-2024
Weatherford College
2023
Yale University
2016-2018
Yale New Haven Hospital
2016
Guizhou Cancer Hospital
2013
Targeting focal adhesion kinase (FAK) renders checkpoint immunotherapy effective in pancreatic ductal adenocarcinoma (PDAC) mouse model. Defactinib is a highly potent oral FAK inhibitor that has tolerable safety profile.We conducted multicenter, open-label, phase I study with dose escalation and expansion phases. In escalation, patients refractory solid tumors were treated at five escalating levels of defactinib gemcitabine to identify recommended II (RP2D). phase, metastatic PDAC who...
Abstract Purpose: This phase Ib/2 trial investigated pembrolizumab-containing trimodality therapy in patients with gastroesophageal junction (GEJ) adenocarcinoma. Patients and Methods: GEJ adenocarcinoma (cT1–3NanyM0) received neoadjuvant chemoradiation (CROSS regimen) followed by surgical resection adjuvant pembrolizumab. The primary endpoints were tolerability the first 16 pathologic complete response [pCR (ypT0N0)]. Secondary included progression-free survival (PFS) overall (OS). An...
Patient-derived cancer organoids (PDOs) hold considerable promise for personalizing therapy selection and improving patient outcomes. However, it is challenging to generate PDOs in sufficient numbers test therapies standard culture platforms. This challenge particularly acute pancreatic ductal adenocarcinoma (PDAC) where most patients are diagnosed at an advanced stage with non-resectable tumors tissue the form of needle biopsies. Here development characterization microfluidic devices...
In a retrospective study of patients with Lynch syndrome vs non‐Lynch and microsatellite instability high colorectal cancer, there were no observed differences immune checkpoint inhibitors toward progression‐free survival or overall survival. Univariate analysis Stage IV showed BRAF V600E mutations associated decreased
Abstract Purpose: KRAS G12C inhibitors can treat KRASG12C-mutant advanced colorectal cancers and pancreatic ductal adenocarcinomas (PDAC), but alterations in Kirsten rat sarcoma (KRAS), EGFR, BRAF, MAP2K1, other genes bypass inhibition reduce therapy efficacy. Our study evaluates the genetic landscape of candidate primary resistance relevant to targeting cancer PDAC. Experimental Design: We analyzed two cohorts (national database Mayo) patients with or PDAC tested next-generation sequencing...
<div>AbstractPurpose:<p><i>KRAS</i><sup>G12C</sup> inhibitors can treat <i>KRAS</i><sup>G12C</sup>-mutant advanced colorectal cancers and pancreatic ductal adenocarcinomas (PDAC), but alterations in Kirsten rat sarcoma (<i>KRAS</i>), <i>EGFR</i>, <i>BRAF</i>, <i>MAP2K1</i>, other genes bypass KRAS inhibition reduce therapy efficacy. Our study evaluates the genetic landscape of...
<p>Venn diagram of candidate resistance alterations from the literature and their distribution among patients with colorectal cancer in national Mayo cohorts</p>
<p>Trend of KRAS G12C variant allele frequency (VAF) in 3 patients: Patient 1 with pancreatic ductal adenocarcinoma (PDAC), Patients 2 & colorectal carcinoma (CRC). FOLFOX = 5-FU, Leucovorin, Oxaliplatin; FOLIRI Irinotecan, FOFLIRINOX Oxaliplatin.</p>
<p>Venn diagram of candidate resistance alterations from the literature and their distribution among patients with pancreatic cancer in national Mayo cohorts.</p>
Antibiotic use may increase hospital length of stay (LOS) among older patients with advanced cancer who are transitioned to comfort measures.We studied a cohort aged ≥65 years were measures during admission from July 1, 2014, through November 30, 2016. We evaluated the association between antibiotic exposure and LOS using Poisson regression model adjusted for age, gender, type, comorbidities, infection, intensive care unit admission.Among 461 cancer, median age was 74 (range: 65-99), 49.0%...
175 Background: Alterations to mismatch repair (MMR) genes such as MLH1, MSH2, MSH6, and PMS2, can lead microsatellite instability-high (MSI-H) tumors. MMR mutations be inherited in Lynch syndrome (LS) but also a result of de novo alterations resulting MSI-H malignancies. Treatment with immune checkpoint inhibitors (ICIs) have been shown improve survival patients (pts) compared systemic chemotherapy. However, there is paucity information the literature respect outcomes pts germline vs...
TPS228 Background: Colorectal cancer (CRC) is the third most frequently diagnosed and second leading cause of cancer-related mortality worldwide. PD-1/PD-L1 inhibition, in combination with other modalities, has demonstrated significant benefit patients (pts) microsatellite instability-high or mismatch repair–deficient CRC. However, these agents have limited, if any, clinical pts stable (MSS) repair–proficient (pMMR) RP2 an enhanced potency oncolytic herpes simplex virus type 1 which...
170 Background: KRAS-mutant colorectal cancer (CRC) has a worse prognosis and greater resistance to therapy, attracting tremendous efforts develop both allele-specific pan-KRAS targeting agents including KRAS G12C G12D inhibitors. CRC demonstrated primary acquired inhibitors, which can be better evaluated by circulating tumor DNA (ctDNA)-based next generation sequencing (NGS) methods without tissue sampling bias. Here, we utilized clinical ctDNA data delineate the landscape of candidate...
Abstract Immune checkpoint inhibitors (ICIs), as a novel class of anticancer therapy, can be more efficacious and less toxic than chemotherapy, but their clinical success is confined to certain tumor types. Elucidating targets, mechanisms scope action, potential synergism with chemotherapy and/or targeted therapies are critical widen indications. Treatment response an ICI targeting programmed death‐1 (anti‐PD‐1) sought understood here by conducting preplanned correlative analysis phase II...
TPS780 Background: Pancreatic adenocarcinoma is an aggressive malignancy with a limited number of therapeutic options. One subset patients (up to 15%) carries germline and/or somatic mutations in homologous recombination repair genes, most notably BRCA1, BRCA2 and PALB2 amongst others, that confer sensitivity PARP inhibition. Combinations inhibitors anti-PD1 immunotherapy have shown activity breast ovarian cancer not yet been thoroughly studied pancreatic cancer. Methods: We designed...
Objectives Systemic therapies for pancreatic neuroendocrine tumors (PNETs) are limited. The combination of bevacizumab and temsirolimus showed significant antitumor activity, but the single-agent activity was unknown. We conducted a single-arm, phase II trial to evaluate efficacy in PNETs. Methods Patients with progressive disease by Response Evaluation Criteria Solid Tumors version 1.1 within 7 months enrollment were eligible 10 mg/kg every 2 weeks. Adverse events assessed according Common...